Beam Competitors
| BEAM Stock | USD 26.52 1.79 7.24% |
Beam Therapeutics vs Galapagos Correlation
Poor diversification
The correlation between Beam Therapeutics and GLPG is 0.74 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Beam Therapeutics and GLPG in the same portfolio, assuming nothing else is changed.
Moving together with Beam Stock
Moving against Beam Stock
| 0.71 | GNLX | Genelux Common | PairCorr |
| 0.68 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.63 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.61 | LYRA | Lyra Therapeutics | PairCorr |
| 0.6 | EVGN | Evogene | PairCorr |
Beam Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Beam Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Beam and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Beam Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Beam Stock performing well and Beam Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Beam Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AGIO | 3.06 | (0.37) | 0.00 | (0.22) | 0.00 | 5.99 | 56.88 | |||
| DNLI | 2.94 | 0.39 | 0.14 | 0.27 | 3.02 | 6.50 | 23.32 | |||
| RXRX | 3.51 | (0.60) | 0.00 | (0.14) | 0.00 | 7.87 | 20.15 | |||
| IBRX | 5.20 | 1.71 | 0.35 | 2.26 | 4.25 | 11.16 | 51.87 | |||
| RCUS | 2.74 | 0.08 | 0.01 | 0.27 | 4.40 | 5.64 | 19.63 | |||
| ETNB | 2.99 | 1.04 | 0.33 | 58.78 | 1.83 | 3.02 | 86.02 | |||
| COGT | 4.75 | 1.71 | 0.63 | 0.59 | 2.27 | 5.71 | 126.24 | |||
| MLYS | 2.56 | (0.47) | 0.00 | (0.23) | 0.00 | 5.87 | 24.91 | |||
| IDYA | 1.99 | 0.00 | (0.01) | 0.08 | 2.26 | 4.86 | 10.56 | |||
| GLPG | 0.99 | 0.07 | 0.02 | 0.22 | 1.23 | 2.62 | 7.99 |
Cross Equities Net Income Analysis
Compare Beam Therapeutics and related stocks such as Agios Pharm, Denali Therapeutics, and Recursion Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGIO | (23.7 M) | (23.7 M) | (20.1 M) | (39.4 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (327.4 M) | 1.6 B | (231.8 M) | (352.1 M) | 673.7 M | 774.8 M | 813.5 M |
| DNLI | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (86.7 M) | (88.2 M) | (36.2 M) | (197.6 M) | 71.1 M | (290.6 M) | (326 M) | (145.2 M) | (422.8 M) | (380.5 M) | (361.5 M) |
| RXRX | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (87 M) | (178.1 M) | (239.4 M) | (328.1 M) | (463.7 M) | (417.3 M) | (396.4 M) |
| IBRX | (2 M) | (2 M) | (2 M) | (2 M) | (6.2 M) | (236.9 M) | (120.8 M) | (96.4 M) | (96.2 M) | (65.8 M) | (221.9 M) | (346.8 M) | (416.6 M) | (583.2 M) | (413.6 M) | (372.2 M) | (353.6 M) |
| RCUS | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (53.1 M) | (49.6 M) | (75.9 M) | (123 M) | 53 M | (267 M) | (307 M) | (283 M) | (254.7 M) | (242 M) |
| COGT | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (18.1 M) | (25.5 M) | (34.5 M) | (30.3 M) | (74.8 M) | (72.3 M) | (132.6 M) | (192.4 M) | (255.9 M) | (230.3 M) | (218.8 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (177.8 M) | (160 M) | (152 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
| GLPG | (3.6 M) | (33.1 M) | (5.7 M) | (8.1 M) | 33.2 M | (118.4 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (305.4 M) | (125.4 M) | (218 M) | 211.7 M | 74.1 M | 66.7 M | 70 M |
Beam Therapeutics and related stocks such as Agios Pharm, Denali Therapeutics, and Recursion Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Beam Therapeutics financial statement analysis. It represents the amount of money remaining after all of Beam Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Beam Therapeutics Competitive Analysis
The better you understand Beam Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Beam Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Beam Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Beam Therapeutics Competition Performance Charts
Five steps to successful analysis of Beam Therapeutics Competition
Beam Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Beam Therapeutics in relation to its competition. Beam Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Beam Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Beam Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Beam Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Beam Therapeutics position
In addition to having Beam Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Makers Thematic Idea Now
Chemicals Makers
Companies developing chemicals for crops, soil as well as human, and animals. The Chemicals Makers theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Makers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Beam Therapeutics Correlation with its peers. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.